Name of the Issue: Innova Captab Limit	red	Last updated on	15-02-2025
1 Type of Issue	Initial Public offer	· · · · · ·	
2 Issue Size (Rs. Mn)	5,700.00		
Fresh Issue (Rs Mn)	3,200.00		
Offer for Sale (Rs Mn)	2,500.00		
*Source: Prospectus for the offer dated D	ecember 26, 2023		
3 Grade of issue along with name of the			
Name	NA		
Grade	NA		
4 Subscription Level (Number of times)	39.17*		
	ls, duplicate bids and Cancelled/withdrawal/duplicate		
applications/RC 10 & Other than RC 10 b	ids and after recategorization		
Source: Post Issue Report			
5 QIB Holding (as a %age of Outstanding	Capital) as disclosed to the stock exchanges		
Particulars		0/	
(i) On Allotment in the offer (1)		11.12%	
(ii) at the end of the 1st Quarter immediate	ally offer the listing	13.88%	
of the issue (December 31, 2023)	ay aner me isung	13.80%	
(iii) at the end of 1st FY (March 31, 2023)		22.71%	
(iv) at the end of 2nd FY (March 31, 2024)		Not Available	
(v) at the end of 3rd FY (March 31, 2026)		Not Available	
(V) at the end of Stur FT (Warch ST, 2020)		Nut Available	

 (v) at the end of 3rd FV (March 31, 2020)*

 *QIB Holding not disclosed as reporting for the relevant period/fiscal year has not been completed.

 (1) Source:Basis of Allotment (Includes allotment to Anchor Investors)

6 Financials of the issuer

			(Rs. in Cores)
Parameters	1st FY (March 31, 2024)	2nd FY (March 31, 2025)*	3rd FY (March 31, 2026)*
Income from operations	1,081.31	Not Available	Not Available
Net Profit for the period	94.35	Not Available	Not Available
Paid-up equity share capital	57.23	Not Available	Not Available
Reserves excluding revaluation reserves	773.67	Not Available	Not Available
*Financials not evallable as repetiting for the relevant of	and has not been completed		

*Financials not available as reporting for the relevant years has not been completed.

7 Trading Status

The equity shares of Innova Captab Limited are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")

The equity shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2024)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2025)*	Not Available
(iii) at the end of 3rd FY (March 31, 2026)*	Not Available
* Trading status not disclosed as the relevant fiscal years have not been completed	

Frading status not disclosed as the relevant fiscal years have not been completed.

8 Change in Directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed/Resigned
(i) at the end of 1st FY (March 31, 2024)	No Change	No Change
(ii) at the end of 2nd FY (March 31, 2025)*	NA	NA
(iii) at the end of 3rd FY (March 31, 2026)*	NA	NA
+ Delever (for each other than a state of the delevel of the delevel of the	E-h	

* Relevant fiscal years have not been completed. Updated till February 15, 2025

9 Status of implementation of project/ commencement of commercial production		
(i) as disclosed in the offer document	Not applicable	
(ii) Actual implementation	Not applicable	
(iii) Reasons for delay in implementation, if any	Not applicable	

10 Status of utilization of issue proceeds

(i) As disclosed in the offer document

			(Rs. in Crores)
Particular	Total estimated amount / expenditure	Fiscal 2024	Fiscal 2025
Repayment and / or prepayment, in part or in full, of	1,444.00	1,444.00	-
certain outstanding loans of our Company			
Investment in our Subsidiary, UML, for repayment and	236.00	236.00	-
/ or prepayment in part or full of outstanding loans			
availed by UML			
Funding our working capital requirements	720.00	100.00	620.00
General corporate purposes	531.09	531.09	-
Total Net Proceeds	2,931.09	2,311.09	620.00
Sourced from the Prospectus for the offer dated Decem	ber 26, 2023.		
(ii) Actual utilization : B116			(Rs. in Crores)
Particular	Total estimated amount / expenditure	Amount utilised as at the end of	Unutilised amount Rs crore
		the guarter (June 2024)	

		the quarter (June 2024)	
Repayment/pre-payment of certain indebtedness	1,444.00	1,444.00	-
Investment in Subsidiary	236.00	236.00	-
Funding Working Capital	720.00	720.00	-
General corporate purposes	531.09	531.09	-
Total Net Proceeds	2,931.09	2,931.09	NIL
Sourced Monitoring agency report dated February 11, 2025			

11	Comments of monitoring agency, if applicable		
	(i) Comments on use of funds		Ĺ
	(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the offer document	No comments	
	(iii) Any other reservations expressed by the monitoring agency about the end use of funds		1
	Monitoring agency report dated February 11, 2025		
12	Pricing Data		
	Designated Stock Exchange	NSE	
	Issue Price (Rs.)	448.00	
	Listing Date	29-Dec-23	

Price parameters	At close of listing day- December 29, 2023	At close of listing day- December 29, 2023 At close of 30th calendar day from listing day ⁽²⁾ At close of 90th calendar day from listing day ⁽²⁾ day ⁽³⁾⁽⁴⁾				As at the end of the 1st FY after the listing of the issue (31st March, 2024) (4)			
				Closing price	High (during the FY)	Low (during the FY)			
Market Price on NSE ⁽⁵⁾	549.85	515.90	454.45	449.45	588.00	443.25			
NIFTY50* ⁽⁵⁾	21,731.40	21,352.60	22123.65	22326.90	22526.60	17312.75			
Sectoral Index ⁽⁶⁾	Not comparable to any of the available sectoral indices Not comparable to any of the available sectoral indices				able sectoral indices				
Price parameters	As at the end of the 2nd FY a				t the end of the 3rd FY after the listing of the issue (31st March, 2026) ⁽¹⁾⁽⁴⁾				
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)			
Market Price on NSE ⁽⁵⁾	NA	NA	NA	NA	NA	NA			
NIFTY50* ⁽⁵⁾	NA	NA	NA	NA	NA	NA			
Sectoral Index ⁽⁶⁾	Not comparable to any of the available sectoral indices Not comparable to any of the available sectoral indices				able sectoral indices				

Source: NSE website

(1) The pricing data is not disclosed as the relevant period/fiscal years have not been completed

(2) 30th calendar day is taken as listing date plus 29 calendar days

(3) 90th calendar day is taken as listing date plus 89 calendar days

(4) High and Low based on intra day prices

(6) In case of reporting dates falling on a trading holiday, values for the trading day immediately preceding the trading holiday have been considered.
 (6) Comparable Sectoral index is not available

PP (Baid)jetterj	Accounting ratio		Face Value per share (Rs.)	As disclosed in offer document*	At the end of 1st FY (March 31, 2024)	At the end of 2nd FY (March 31, 2025)**	At the end of 3rd FY (Marc 31, 2026)
Pictor Distribution Distribution <thdistribution< th=""> Distribution</thdistribution<>	EPS (Basic)					2023)	31.2020
PF Image: constraint of the state of the st			10	14.16	18.66	Not Available	Not Availab
Former Personand is Limited 5 36,70 46,94 Not Auslands							
Inne (and (and) Inner) 2 16.49 2.80 M24 And 100 M24			-				
April Prome Linkid 2 46.89 64.02 Not Audioals No							Not Availat
							Not Availat
Partnerwick Partnerwick National bind 1 918 713 National bind							Not Availat
NATCO Pharma Linead: 2 39.18 77.34 Not Available Not Available <t< td=""><td></td><td></td><td>2</td><td>52.34</td><td>35.66</td><td>Not Available</td><td>Not Availab</td></t<>			2	52.34	35.66	Not Available	Not Availab
En En Histonnes Linted 1 28.07 28.87 NAA Avaibable NAA South Pharmaculcala Linted 2 15.62 0.05 NAA Avaibable NAA South Pharmaculcala Linted 2 15.62 0.05 NAA Avaibable NAA Pre South Pharmaculcala Linted 2 0.07 9.82 NAA Avaibable NAA Pre South Pharmaculcala Linted 2 0.07 9.82 NAA Avaibable NAA Pre South Pharmaculcala Linted 2 0.07 NAA NAA Avaibable NAA All Company - - NAA 0.07 NAA Avaibable NAA All Company - - NAA 0.07 NAA Avaibable NAA All Commanda and 2 26.61 4.62 NAA Avaibable NAA All Commanda and 2 22.71 31.61 NAA Avaibable NAA NAAO Consolded 1 0.07 NAA Avaibable NAA NAA Avaibable NA			2	20.18	77.34	Not Available	Not Availat
Indoo Reneales Limited 2 16.6 10.53 Net Analable Net Alababe Net							Not Availab
Suren Pharmazeudals Limited 1 16.16 11.00 Nac Available			1				Not Availat
Windlas Blotten Limited 5 19.7 27.97 New Available							Not Availab
Per Consoliated 28.00 34.20 Not Available			5				Not Availat
Instant Instant <t< td=""><td></td><td></td><td>Ŭ</td><td></td><td></td><td></td><td>Not Availal</td></t<>			Ŭ				Not Availal
Company 10 MA* 24.09 Not Available Not A Hadtert Average - Peer Group Torrent Pharmacoutcola Linted 5 57.61 63.14 Net Available Not A Launa Laba Linted 2 26.53 131.66 Net Available Not Availa	P/E						
Industry Average - Peer Group - - - - Torret Pharmacoucioal Limited 5 57.61 63.14 Not Available No			10	NA [#]	24.09	Not Available	Not Availat
Torent Planmacuitals Limited 5 67.61 63.14 Net Available Net Available Ajanta Planma Limited 2 25.53 31.16.0 Net Available							
Laura Lab Limited 2 26.33 131.66 Not Available			5	57.61	53.14	Not Available	Not Availat
Agata Braina Linited 2 42.91 34.42 Not Available Net Paramacuicals Linited - - - - - - - - - Notable NotA - - Notable NotA - Notable NotA - Notable NotA -							Not Availal
Pharmacoulicital Limited 2 9,90 12,31 Not Available		Ajanta Pharma Limited	2	42.91			Not Availat
NATCO Pharma Limited 2 19.90 12.31 Nat Available Nata Eris Lifesciones Limited 1 33.01 29.26 Nat Available Nata Suven Pharmaeucitas Limited 1 37.13 57.38 Nata Available Nata Poer Group: Consolidated 1 37.13 57.38 Nata Available Nata Ronw % Essent 32.16 45.99 Nata Nata </td <td></td> <td>J. B. Chemicals and</td> <td>2</td> <td>28.61</td> <td>46.28</td> <td>Not Available</td> <td>Not Availab</td>		J. B. Chemicals and	2	28.61	46.28	Not Available	Not Availab
Fish Lifesciences Linited 1 33.01 29.26 Net Available		Pharmaceuticals Limited					
Index Remedies Limited 2 27.4 31.21 Nat Available Not A Biven Pharmacultals Limited 5 22.04 18.24 Not Available Not A RNW % Suren Pharmacultals Limited 5 22.04 18.24 Not Available Not A RNW % Suren Pharmacultals Limited 5 22.04 18.24 Not Available Not A Row % Suren Pharmacultals Limited 0 24.55% 11.35% Not Available Not A Interret Pharmacultals Limited 2 0.11% 24.55% Not Available Not A Aganta Pharmacultals Limited 2 19.74% 3.05% Not Available		NATCO Pharma Limited	2	19.90	12.31	Not Available	Not Availat
Surve Pharmaceuticals Limited 1 37,13 57,38 Not Available		Eris Lifesciences Limited	1	33.01	29.26	Not Available	Not Availab
Windlas Biotech Limited 5 22.04 18.24 Net Available Net A RoNW %. Issuer:		Indoco Remedies Limited	2		31.21	Not Available	Not Availat
Peer Group: (Consolidated) 32.16 45.99 Same Company 10 24.58% 11.35% Not Available Not Available RoNW % Industry Average - Peer Group 1 13.5% Not Available			1		57.38	Not Available	Not Availab
RoNW % Issue: Image: State industry Average - Peer Group			5			Not Available	Not Availab
Company 10 24.58% 11.35% Not Available Not Avai				32.16	45.99		
Industry Average - Peer Group	RoNW %						
Torrent Pharmaceuticals Limited 5 20,11% 24,15% Net Available Net Availabl			10	24.58%	11.35%	Not Available	Not Availab
Laurus Labs Limited 2 19.74% 3.95% Not Available Not Available <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>							
Ajanta Pharma Limited217.3%22.8%Not AvailableNot AJ. B. Chemicals and216.54%18.90%Not AvailableNot APharmaceuticals Limited214.84%23.72%Not AvailableNot ANATCO Pharma Limited117.10%15.35%Not AvailableNot ALindoco Remedies Limited117.10%15.35%Not AvailableNot ALindoco Remedies Limited123.72%Not AvailableNot AvailableNot AvailableSuven Pharmaceuticals Limited123.70%10.61%12.93%Not AvailableNot AvailableNAV per shareSuven Pharmaceuticals Limited510.61%12.93%Not AvailableNot AvailableNAV per shareSuven Pharmaceuticals Limited510.61%14.520Not AvailableNot AvailableNAV per shareSuven Pharmaceuticals Limited5182.97202.57Not AvailableNot AvailableNAV per shareIndustry Average - Peer Group74.9276.27Not AvailableNot Available							Not Availab
J. B. Chemicals and 2 16.54% 18.90% Not Available Not A Pharmaceuticals Limited 2 14.84% 23.72% Not Available Not A NATCO Pharma Limited 2 14.84% 23.72% Not Available Not A Indoco Remedies Limited 1 17.10% 15.35% Not Available Not A Indoco Remedies Limited 2 13.83% 8.74% Not Available Not A Suven Pharmaceuticals Limited 1 23.70% 14.64% Not Available Not A Windlas Biotech Limited 5 10.61% 12.93% Not Available Not A NAV per share Issuer: - - - - Company 10 57.60 145.20 Not Available Not A Industry Average - Peer Group - - - - Torrent Pharmaceuticals Limited 5 182.97 20.257 Not Available Not Available J. B. Chemicals and 2 267.41 283.31 Not Available Not Available Not Available Pharmaceuticals Limited 2 267.41 283.31 Not Available Not Available Not Company 1 160.655 190.12<			=				Not Availab
Pharmaceuticals Limited 2 14.84% 23.72% Not Available N							Not Availab
NATCO Phama Limited214.84%23.72%Not AvailableNot AEris Lifesciences Limited117.10%15.35%Not AvailableNot AIndoco Remedies Limited213.83%8.74%Not AvailableNot AStruen Pharmaceuticals Limited123.70%14.64%Not AvailableNot AWindlas Biotech Limited510.61%12.93%Not AvailableNot ANAV per shareIssuer:16.05%16.14%Not AvailableNot ACompany1057.60145.20Not AvailableNot AIndustry Average - Peer Group1057.60145.20Not AvailableNot AIndustry Average - Peer Group1274.92Not AvailableNot AIndustry Average - Peer Group274.9276.27Not AvailableNot AIndustry Average - Peer Group2267.41283.31Not AvailableNot AIndustry Average - Peer GroupTorrent Pharmaceuticals Limited2267.41283.31Not AvailableNot AI, B. Chemicals and2320.36188.37Not AvailableNot AI, B. Chemicals and2264.21326.79Not AvailableNot AIndoco Remedies Limited1160.25190.12Not AvailableNot AIndoco Remedies Limited168.1600.56Not AvailableNot AvailableMind as Biotech Limited168.1			2	16.54%	18.90%	Not Available	Not Availab
Eris Lifesciences Limited117.10%15.35%Not AvailableNot AIndoco Remedies Limited213.83%8.74%Not AvailableNot ASween Phramaceuticals Limited123.70%14.64%Not AvailableNot AWindlas Biotech Limited510.61%12.93%Not AvailableNot AWindlas Biotech Limited510.61%12.93%Not AvailableNot APeer Group: (Consolidated)510.61%12.93%Not AvailableNot ANAV per shareIssuer:1057.60145.20Not AvailableNot AIndustry Average - Peer GroupTorrent Phramaceuticals Limited5182.97202.57Not AvailableNot AJ. B. Chemicals and2267.41283.31Not AvailableNot AAjata Pharma Limited220.261320.36188.37Not AvailableNot ANatr Co Pharma Limited2264.21326.79Not AvailableNot ANatr Co Pharma Limited1160.85190.12Not AvailableNot AAndroco Remedies Limited168.1680.56Not AvailableNot AMarco Concepticals Limited168.1680.56Not AvailableNot AMarco Pharma Limited5192.02216.33Not AvailableNot ANot Available168.1680.56Not AvailableNot ANot Available115.8192.02216.33Not Available <td< td=""><td></td><td></td><td></td><td></td><td>0.0 70.07</td><td></td><td></td></td<>					0.0 70.07		
Indoco Remedies Limited213.83%8.74%Not AvailableNot ASurven Pharmaceuticals Limited123.70%14.64%Not AvailableNot AWindlas Biotech Limited510.61%12.93%Not AvailableNot APeer Group: (Consolidated)16.05%16.14%Not AvailableNot ANAV per shareIssuer:			-				Not Availab
Suven Pharmaceuticals Limited 1 03.70% 14.64% Not Available Not A Windias Biotech Limited 5 10.61% 12.93% Not Available Not A Were froup: (Consolidated) 16.05% 16.14% Not Available Not A NAV per share Issuer: 10 57.60 145.20 Not Available Not A Industry Average - Peer Group 10 57.60 145.20 Not Available Not A Torrent Pharmaceuticals Limited 5 182.97 202.57 Not Available Not A Ajanta Pharma Limited 2 74.92 76.27 Not Available Not A J. B. Chemicals and 2 320.36 188.37 Not Available Not A NATCO Pharma Limited 2 264.21 326.79 Not Available Not A MATCO Pharma Limited 1 160.85 190.12 Not Available Not A Algoe Rendies Limited 1 10.26.27 Not Available Not A Bird Comman Limited 2 267.41 283.31 Not Available Not A Ajanta Pharma Limited 2 264.21 326.79 Not Available Not A NATCO Pharma Limited 1 160.85							Not Availat
Windlas Biotech Limited510.61%12.93%Not AvailableNot APeer Group; (Consolidated)16.05%16.05%16.14%Not AvailableNot ANAV per shareIssuer:Company1057.60145.20Not AvailableNot AIndustry Average - Peer GroupTorrent Phramaceuticals Limited5182.97202.57Not AvailableNot ATorrent Phramaceuticals Limited274.9276.27Not AvailableNot AAjanta Pharma Limited2267.41283.31Not AvailableNot AJ. B. Chemicals and2320.36188.37Not AvailableNot APharmaceuticals Limited1160.85190.12Not AvailableNot AIndico Remedies Limited2264.21326.79Not AvailableNot AMATCO Pharma Limited2111.58120.40Not AvailableNot AMaraceuticals Limited168.1680.56Not AvailableNot AMaraceuticals Limited5192.02216.33Not AvailableNot A			-				Not Availab
Peer Group: (Consolidated) 16.05% 16.14% Not Available Not A NAV per share Issuer:							Not Availab
Issuer: Insuer: Insuer: <t< td=""><td></td><td></td><td>5</td><td></td><td></td><td></td><td>Not Availab</td></t<>			5				Not Availab
Company1057.60145.20Not AvailableNot AIndustry Average Peer GroupTorrent Pharmaceuticals Limited5182.97202.57Not AvailableNot ALaurus Labs Limited274.9276.27Not AvailableNot AAjanta Pharma Limited2267.41283.31Not AvailableNot AJ. B. Chemicals and2320.36188.37Not AvailableNot APharmaceuticals Limited2264.21326.79Not AvailableNot APharmaceuticals Limited1160.85190.12Not AvailableNot AEris Lifesciences Limited2111.58120.40Not AvailableNot ABurne Commander168.1680.56Not AvailableNot AWindias Biotech Limited5192.02216.33Not AvailableNot A	NAV was above			16.05%	16.14%	Not Available	Not Availab
Industry Average - Peer GroupTorrent Pharmaceuticals Limited5182.97202.57Not AvailableNot ALaurus Labs Limited276.27Not AvailableNot AAjanta Pharma Limited2267.41283.31Not AvailableNot AJ. B. Chemicals and2320.36188.37Not AvailableNot APharmaceuticals Limited2264.21326.79Not AvailableNot AMATCO Pharma Limited1160.65190.12Not AvailableNot AEris Lifescinces Limited1160.85190.12Not AvailableNot AIndoco Remedies Limited2111.58120.40Not AvailableNot ASurven Pharmaceuticals Limited5192.02216.33Not AvailableNot A	NAV per share		10	57.00	145.00	Net Aveileble	Net Aveilet
Torrent Pharmaceuticals Limited5182.97202.57Not AvailableNot ALaurus Labs Limited274.9276.27Not AvailableNot AAjanta Pharma Limited2267.41283.31Not AvailableNot AJ. B. Chemicals and2320.36188.37Not AvailableNot APharmaceuticals Limited2264.21326.79Not AvailableNot ANATCO Pharma Limited2264.21326.79Not AvailableNot AIndico Remedies Limited1160.85190.12Not AvailableNot AIndico Remedies Limited2111.58120.40Not AvailableNot ASuven Pharmaceuticals Limited5192.02216.33Not AvailableNot A			10	57.60	145.20	NOL AVAIIADIE	NOL AVAIIAD
Laurus Labs Limited274.9276.27Not AvailableNot AAjanta Pharma Limited2267.41283.31Not AvailableNot AJ. B. Chemicals and2320.36188.37Not AvailableNot APharmaceuticals Limited2264.21326.79Not AvailableNot ANATCO Pharma Limited1160.85190.12Not AvailableNot AEris Lifesciences Limited1160.85190.12Not AvailableNot ASuven Pharmaceuticals Limited5192.02216.33Not AvailableNot A			5	182.07	202 57	Not Available	Not Availab
Ajanta Pharma Limited2267.41283.31Not AvailableNot AJ. B. Chemicals and2320.36188.37Not AvailableNot APharmaceuticals Limited7264.21326.79Not AvailableNot ANATCO Pharma Limited2264.21326.79Not AvailableNot AEris Lifesciences Limited1160.85190.12Not AvailableNot AIndoco Remedies Limited2111.58120.40Not AvailableNot ASwen Pharmaceuticals Limited168.1680.56Not AvailableNot AWindlas Biotech Limited5192.02216.33Not AvailableNot A							Not Availab
J. B. Chemicals and Pharmaceuticals Limited2320.36188.37Not AvailableNot ANATCO Pharma Limited2264.21326.79Not AvailableNot AEris Lifesciences Limited1160.85190.12Not AvailableNot AIndoco Remedies Limited2111.58120.40Not AvailableNot ASuven Pharmaceuticals Limited168.1680.56Not AvailableNot AWindlas Biotech Limited5192.02216.33Not AvailableNot A							Not Availat
Pharmaceuticals LimitedNATCO Pharma Limited2264.21326.79Not AvailableNot AEris Lifesciences Limited1160.85190.12Not AvailableNot AIndoco Remedies Limited2111.58120.40Not AvailableNot ASuven Pharmaceuticals Limited568.1680.56Not AvailableNot AWindias Biotech Limited5190.22216.33Not AvailableNot A							Not Availab
NATCO Pharma Limited2264.21326.79Not AvailableNot AEris Lifesciences Limited1160.85190.12Not AvailableNot AIndoco Remedies Limited2111.58120.40Not AvailableNot ASwren Pharmaceuticals Limited168.1680.56Not AvailableNot AWindlas Biotech Limited5192.02216.33Not AvailableNot A			2	520.50	100.37	NUL AVAIIDUR	NUL AVdildi.
Eris Lifesciences Limited1160.85190.12Not AvailableNot AIndoco Remedies Limited2111.58120.40Not AvailableNot ASuven Pharmaceuticals Limited168.1680.56Not AvailableNot AWindlas Biotech Limited5199.22216.33Not AvailableNot A			2	264.21	326 70	Not Available	Not Availab
Indoco Remedies Limited2111.58120.40Not AvailableNot ASuven Pharmaceuticals Limited168.1680.56Not AvailableNot AWindlas Biotech Limited5192.02216.33Not AvailableNot A							Not Availat
Suven Pharmaceuticals Limited 1 68.16 80.56 Not Available Not A Windlas Biotech Limited 5 192.02 216.33 Not Available Not A							Not Availat
Windlas Biotech Limited 5 192.02 216.33 Not Available Not A							Not Availab
							Not Availat
		Peer Group: (Consolidated)	0	182.50	187.19	Not Available	Not Availab

Notes

* Source: Prospectus for the offer dated December 26, 2023.

^ Financial information of the company as at or for the financial year ended June 30, 2023

**Not available as the relevant fiscal years have not been completed/information not disclosed

Key ratios for the Company for the three fiscal years stated above are/shall be calculated as follows:

(i) Basic earnings per Equity Share are computed in accordance with Indian Accounting Standard 33 'Earnings per Share' for issuer company, notified by the Companies (Indian Accounting Standards) Rules, 2015, as amended. (ii) P/E - Closing Market Price as of relevant fiscal year end on BSE / Basic EPS for relevant fiscal

(iii) RONW - Return on Net worth attributable to the owners of our Company (%) = Restated profit / (loss) for the year attributable to owners of the Company / Net worth attributable to owners of the Company (iv) NAV per share - Networth attributable to owners of the Company # Not meaningful as the company/companies has/have incurred losses

14 Any other material information

Date	Announcement
29-Dec-23	Listing of equity shares of Innova Captab Limited
11-Jan-24	Company informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/01/2024, inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2023
03-Feb-24	Monitoring Agency Report issues in the respect of the Utilization of the proceeds of the Initial Public Offer ("IPO") of the Company for the quarter ended December 31, 2023
13-Feb-24	Un-Audited (Standalone and Consolidated) Financial Results of the Company for the quarter and nine months ended December 31, 2023.
14-Mar-24	Resignation of Chief Financial Officer (CFO)
21-Mar-24	Intimation Regarding Re-Commencement Of A Manufacturing Facility Of Sharon Bio-Medicine Limited' (Material Subsidiary Of The Company)
29-Mar-24	Board Meeting Outcoe-Appointment of CFO & Acquisition of propert in Baddi, Authorization Of Key Managerial Personnel Under Regulation 30(5) Of SEBI LODR, 2015 To Determine Materiality Of An Event Or Information
10-Apr-24	Company manufated unar. Sharon Borweedche Emitted International Subsidiary of the Company), minis board Swening neuron wednesday, April Totir, 2024, has approved the purchase of a rand and pursuant to Board approval dated April 10th, 2024, Sharon Bio-Wedicine Limited has entered into an agreement on April 10, 2024 for purchasing of land admeasuring 4,410 sq. mtr. (5.86 Bigha) situated at Khasra number 1031 & 1032, Central Hope Tourne Selarui Debradui pur board thread board approval the State of Uttrakbaad
09-May-24	Monitoring Agency Report issues in the respect of the Utilization of the proceeds of the Initial Public Offer ("IPO") of the Company for the quarter ended March 31, 2024
20-May-24	Company informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024, inter alia, to consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the Financial Year Ended March 31, 2024
29-May-24	Audited (Standalone and Consolidated) Financial Results of the Company for the F.y. March 31, 2024.
16-Jul-24	Intimation Regarding Change Of Corporate Identification Number Pursuant To The Listing Of Equity Shares Of The Company
23-Jul-24	Announcement under Regulation 30 (LODR)-Monitoring Agency Report
26-Jul-24	Announcement Under Regulation 30 Of SEBI(LODR)- Sharon Bio-Medicine Limited (Material Subsidiary Of The Company) Has Entered Into An Agreement To Purchase Land.
09-Aug-24	Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. August 09, 2024.
09-Aug-24	Quarterly Result For Q1 Of FY 2024 (Consolidated And Standalone)
23-Aug-24	Reg. 34 (1) Annual Report.
24-Aug-24	Business Responsibility and Sustainability Reporting (BRSR)
06-Nov-24	Pursuant To The Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, (Listing Regulations'), We Wish To Inform You That Our Upcoming Jammu Facility Received 'Drug Manufacturing License' Vide Letter No. CLJK202406146 Dated November 06, 2024 From Government Of Jammu And Kashmir, Department Of Health And Medical Education, Drug Control Organisation, Jammu.
07-Nov-24	Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. November 07, 2024.
07-Nov-24	Statement For Deviation(S) Or Variation(S) Pursuant To Regulation 32 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter And Half Year Ended September 30, 2024
11-Nov-24	Announcement under Regulation 30 (LODR)-Monitoring Agency Report
14-Jan-25	Disclosure under Regulation 30A of LODR - Commencement of operation of New Jammu facility.
20-Jan-25	Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Reguirements) Regulations, 2015 -Shifting Of Registered Office Of Sharon Bio-Medicine Limited, Material Subsidiary Of The Company.
20-Jan-25	Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Sale Of Property Of Sharon Bio-Medicine Limited, Material Subsidiary Of The Company.
05-Feb-25	Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. February 05, 2025
05-Feb-25	Approval Of The Un-Audited (Standalone And Consolidated) Financial Results For The Quarter And Nine Months Ended December 31, 2024
11-Feb-25	Announcement under Regulation 30 (LODR)-Monitoring Agency Report

Note: The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable. For further updates and information, please refer to the website of the Stock Exchanges i.e. www.bseindia.com and / or www.nseindia.com

Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by JM Financial Limited ("JM Financial") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012.

This information is gathered, inter-alia, from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and / or the National Stock Exchange of India Limited ("NSE" and together with the BSE, the "Stock Exchanges") from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

Nothing in this information is intended by JM Financial to be construed as legal, regulatory, accounting, tax or other advice. While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, JM Financial does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither JM Financial nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement. JM Financial does not undertake to update the information contained herein except as required by applicable law or regulation.